Abstract

The Role of Immunotherapy in the Treatment of Rheumatoid Arthritis: Emerging Strategies and Future Directions

Author(s): Emma Scott*

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic inflammation and progressive joint destruction. The treatment landscape of RA has evolved considerably over the past few decades, shifting from traditional disease-modifying antirheumatic drugs (DMARDs) to the advent of biologic agents and more recently, targeted immunotherapies. Immunotherapy in RA aims to modulate the immune response and prevent tissue damage by targeting specific components of the immune system, such as pro-inflammatory cytokines, B cells, and T cells. This article reviews the current role of immunotherapy in RA management, focusing on the mechanisms, clinical efficacy, and safety profiles of biologic therapies, Janus kinase (JAK) inhibitors, and emerging strategies. Additionally, the article discusses the challenges and future directions of immunotherapy in RA, including personalized medicine approaches and the optimization of long-term therapy.